Compare Cadila Healthcare with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DIVIS LABORATORIES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DIVIS LABORATORIES CADILA HEALTHCARE/
DIVIS LABORATORIES
 
P/E (TTM) x 13.7 34.2 40.1% View Chart
P/BV x 2.3 6.4 35.4% View Chart
Dividend Yield % 1.5 1.0 159.3%  

Financials

 CADILA HEALTHCARE   DIVIS LABORATORIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
DIVIS LABORATORIES
Mar-19
CADILA HEALTHCARE/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs4321,639 26.4%   
Low Rs3061,115 27.5%   
Sales per share (Unadj.) Rs128.6186.3 69.0%  
Earnings per share (Unadj.) Rs18.551.0 36.4%  
Cash flow per share (Unadj.) Rs24.457.3 42.6%  
Dividends per share (Unadj.) Rs3.5016.00 21.9%  
Dividend yield (eoy) %0.91.2 81.6%  
Book value per share (Unadj.) Rs101.5261.8 38.8%  
Shares outstanding (eoy) m1,023.74265.47 385.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.97.4 38.9%   
Avg P/E ratio x19.927.0 73.7%  
P/CF ratio (eoy) x15.124.0 63.0%  
Price / Book Value ratio x3.65.3 69.2%  
Dividend payout %18.931.4 60.1%   
Avg Mkt Cap Rs m378,170365,592 103.4%   
No. of employees `00012.411.8 105.0%   
Total wages/salary Rs m21,2415,423 391.7%   
Avg. sales/employee Rs Th10,585.04,175.1 253.5%   
Avg. wages/employee Rs Th1,707.8457.7 373.1%   
Avg. net profit/employee Rs Th1,526.51,141.8 133.7%   
INCOME DATA
Net Sales Rs m131,65649,463 266.2%  
Other income Rs m2,0111,556 129.2%   
Total revenues Rs m133,66751,019 262.0%   
Gross profit Rs m29,73118,718 158.8%  
Depreciation Rs m5,9861,689 354.4%   
Interest Rs m1,93535 5,528.6%   
Profit before tax Rs m23,82118,551 128.4%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,3035,023 105.6%   
Profit after tax Rs m18,98713,527 140.4%  
Gross profit margin %22.637.8 59.7%  
Effective tax rate %22.327.1 82.2%   
Net profit margin %14.427.3 52.7%  
BALANCE SHEET DATA
Current assets Rs m84,98146,501 182.8%   
Current liabilities Rs m73,4258,468 867.1%   
Net working cap to sales %8.876.9 11.4%  
Current ratio x1.25.5 21.1%  
Inventory Days Days75131 57.0%  
Debtors Days Days11086 127.6%  
Net fixed assets Rs m133,49325,797 517.5%   
Share capital Rs m1,024531 192.9%   
"Free" reserves Rs m102,83968,962 149.1%   
Net worth Rs m103,86369,493 149.5%   
Long term debt Rs m39,4970-   
Total assets Rs m234,83180,383 292.1%  
Interest coverage x13.3531.0 2.5%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.60.6 91.1%   
Return on assets %8.916.9 52.8%  
Return on equity %18.319.5 93.9%  
Return on capital %18.326.7 68.4%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m48,40441,238 117.4%   
Fx outflow Rs m11,59312,405 93.5%   
Net fx Rs m36,81128,833 127.7%   
CASH FLOW
From Operations Rs m28,8239,543 302.0%  
From Investments Rs m-57,387-6,854 837.3%  
From Financial Activity Rs m18,846-2,459 -766.3%  
Net Cashflow Rs m-7,105230 -3,094.5%  

Share Holding

Indian Promoters % 74.8 52.0 143.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 11.8 70.3%  
FIIs % 5.9 19.0 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.2 64.0%  
Shareholders   44,069 31,796 138.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  PIRAMAL ENTERPRISES  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Nov 13, 2019 10:49 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS